160 related articles for article (PubMed ID: 22995972)
1. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
[TBL] [Abstract][Full Text] [Related]
3. Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.
Daly EJ; Kent JM; Janssens L; Newcomer JW; Hüsken G; De Boer P; Tritsmans L; Schmidt ME
Ann Clin Psychiatry; 2013 Aug; 25(3):173-83. PubMed ID: 23926573
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
[TBL] [Abstract][Full Text] [Related]
5. Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics.
de Waal EJ; Desmidt M; Korte S; Niehoff M; Chase K; Arrowsmith W; Lampo A
J Appl Toxicol; 2014 Sep; 34(9):974-92. PubMed ID: 24105799
[TBL] [Abstract][Full Text] [Related]
6. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
[TBL] [Abstract][Full Text] [Related]
8. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
[TBL] [Abstract][Full Text] [Related]
10. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM
Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985
[TBL] [Abstract][Full Text] [Related]
11. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
Liu-Seifert H; Osuntokun OO; Feldman PD
Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
[TBL] [Abstract][Full Text] [Related]
15. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
Moriguchi S; Bies RR; Remington G; Suzuki T; Mamo DC; Watanabe K; Mimura M; Pollock BG; Uchida H
J Clin Psychopharmacol; 2013 Oct; 33(5):682-5. PubMed ID: 23899638
[TBL] [Abstract][Full Text] [Related]
16. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia.
Shen JH; Zhao Y; Rosenzweig-Lipson S; Popp D; Williams JB; Giller E; Detke MJ; Kane JM
J Psychiatr Res; 2014 Jun; 53():14-22. PubMed ID: 24613032
[TBL] [Abstract][Full Text] [Related]
17. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
Kramer MS; Last B; Getson A; Reines SA
Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
[TBL] [Abstract][Full Text] [Related]
18. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods.
Chen L; Ascher-Svanum H; Stauffer V; Kinon BJ; Kollack-Walker S; Ruberg S
Schizophr Res; 2009 Aug; 113(1):34-40. PubMed ID: 19564097
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D₂-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D₂-receptor occupancy.
Hoeben E; Neyens M; Mannaert E; Schmidt M; Vermeulen A
Clin Pharmacokinet; 2013 Nov; 52(11):1005-15. PubMed ID: 23754735
[TBL] [Abstract][Full Text] [Related]
20. Evidence for onset of antipsychotic effects within the first 24 hours of treatment.
Kapur S; Arenovich T; Agid O; Zipursky R; Lindborg S; Jones B
Am J Psychiatry; 2005 May; 162(5):939-46. PubMed ID: 15863796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
